Gastric precancerous lesions:occurrence, development factors, and treatment

Yue Cao; Dongcai Wang; Guiyun Mo; Yinghui Peng; Zengzheng Li

doi:10.3389/fonc.2023.1226652

Gastric precancerous lesions:occurrence, development factors, and treatment

Front Oncol. 2023 Aug 30:13:1226652. doi: 10.3389/fonc.2023.1226652. eCollection 2023.

Authors

Yue Cao¹, Dongcai Wang¹, Guiyun Mo², Yinghui Peng¹, Zengzheng Li^{3

4

5

6

7}

Affiliations

¹ Emergency of Department, Yunnan Provincial Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, China.
² Emergency Teaching and Research Department of the First Clinical School of Yunnan University of Traditional Chinese Medicine, Kunming, China.
³ Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
⁴ Yunnan Province Clinical Center for Hematologic Disease, The First People's Hospital of Yunnan Province, Kunming, China.
⁵ Yunnan Blood Disease Hospital, The First People's Hospital of Yunnan Province, Kunming, China.
⁶ National Key Clinical Specialty of Hematology, The First People's Hospital of Yunnan Province, Kunming, China.
⁷ Yunnan Province Clinical Research Center for Hematologic Disease, The First People's Hospital of Yunnan Province, Kunming, China.

Abstract

Patients with gastric precancerous lesions (GPL) have a higher risk of gastric cancer (GC). However, the transformation of GPL into GC is an ongoing process that takes several years. At present, several factors including H.Pylori (Hp), flora imbalance, inflammatory factors, genetic variations, Claudin-4, gastric stem cells, solute carrier family member 26 (SLC26A9), bile reflux, exosomes, and miR-30a plays a considerable role in the transformation of GPL into GC. Moreover, timely intervention in the event of GPL can reduce the risk of GC. In clinical practice, GPL is mainly treated with endoscopy, acid suppression therapy, Hp eradication, a cyclooxygenase-2 inhibitor, aspirin, and diet. Currently, the use of traditional Chinese medicine (TCM) or combination with western medication to remove Hp and the use of TCM to treat GPL are common in Asia, particularly China, and have also demonstrated excellent clinical efficacy. This review thoroughly discussed the combining of TCM and Western therapy for the treatment of precancerous lesions as conditions allow. Consequently, this review also focuses on the causes of the development and progression of GPL, as well as its current treatment. This may help us understand GPL and related treatment.

Keywords: H.pylori; gastric cancer; gastric precancerous lesions; traditional Chinese medicine; treatment.

Publication types

Review

Grants and funding

The research was supported by the project of Yunnan Blood Disease Clinical Medical Center (2021LCZXXF-XY09 and 2022LCZXKF-XY01) and Yunnan Provincial Department of Science and Technology—Kunming Medical University Joint Special Project on Applied Basic Research (202301AY070001-064). This research was also supported by the following projects: Traditional Chinese Medicine Joint Special Project - General Project (202101AZ070001-016), Traditional Chinese Medicine Joint Project - Youth Project (2019FF002 (-080)).